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Abstract
Background: Both regulatory T cells (Tregs) and PD-1/PD-L1 pathway were critically involved in HCV viral
persistence. However, the association between them was not well investigated. Herein, we aimed to investigate
the distributional profiles of Tregs subsets and association between PD-1 expression on these subsets and
development of HCV long-term persistence.
Methods: CD45RA and CD27 were employed to separate peripheral Tregs as naïve/central memory/effector
memory/effector subsets. The phenotypic characteristics and PD-1 expression of Tregs were studied by flow
cytometry.
Results: In the present study, the majority of Tregs was identified as central memory phenotype in chronic
hepatitis C patients compared with nearly equal contribution of naïve and central memory subsets in healthy
individuals. PD-1 expression was elevated in all CD4+ T cell subset in chronic HCV infected patients, including
Tregs. Of note, higher level of PD-1 expression was found on TEM- and effector-Treg than naïve- and TCM-Tregs
subsets. The ratio of TEM-Tregs/naive-Tregs and TEM-Tregs/TCM-Tregs regarding to PD-1 MFI were significantly
lower in CHC patients compared to controls.
Conclusions: Our study indicated that distinctive characteristics of PD-1 expression on Tregs in HCV infection
suggests associated with impaired adaptive immunity as well as viral long-term persistence. The cross talk between
Treg cells and PD-1 induced inhibition in chronic HCV infection deserved further exploration for HCV infection
associated immune pathogenesis.
Introduction
Hepatitis C virus (HCV) infection presents a major glo-
bal health challenge, with an estimation of more than
180 million infected patients worldwide and three
to four million newly-infected cases annually [1,2].
Although some breakthroughs were reached recently in
the treatment of hepatitis C [3-5], HCV infection is still
far away from effective prevention by vaccination and
has become one of the most important causes of
chronic hepatitis, cirrhosis, and hepatocellular carci-
noma around the world.
It is well documented [6-8]that duration and intensity
of HCV-specific CD4
+ T cell responses played an
important role in determining the clinical outcomes of
acute self-recovery or long-term viremic persistence fol-
lowing acute HCV infection. Vigorous virus-specific
CD4
+ T cell responses led to virus clearance in HCV
acute-resolved individuals. The failure of effective CD4
+
T cell immune responses to clean virus was associated
with chronic liver disease and HCV viral persistence.
Tregs were defined as a subset of CD4
+T lymphocytes,
highly expressing CD25 (interleukin-2 receptor a-chain)
on the cell surface and transcription factor Foxp3 intra-
cellularly and occupied 5% of peripheral CD4
+ Tl y m -
phocytes [9-11]. Tregs contributed critically to
suppression of HCV-specific lymphocyte proliferation,
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any medium, provided the original work is properly cited.differentiation and cytokine secretion [12-14], but their
complicated mechanisms involved in HCV persistence
were still obscure.
Another important negative regulating mechanism was
the involvement of PD-1/PD-L1 pathway. PD-1 (pro-
grammed cell death-1) belongs to the CD28 family and
is expressed on activated T, B, and myeloid cells. PD-1
and its ligand PD-L1 deliver inhibitory signals that regu-
late the balance between effector T cell activation and
immune-mediated tissue damage [15,16]. PD-1 knockout
C57BL/6 or BALB/c mice were shown to develop lupus-
like glomerulonephritis and dilated cardiomyopathy
[17,18] and treatment of activated T cells with anti-PD-
L1 antibody in vitro resulted in reduction of T cell pro-
liferation and IFN-g secretion [19]. Several studies indi-
cated that PD-1/PD-L1 pathway was critically involved
in HCV long-term persistence and was regarded as a
potential novel target for restoring function of exhausted
HCV-specific T cell responses [20-22].
Since inhibition of the effector T cells by Tregs and
the PD-1/PD-L1 pathway were described as mechanisms
responsible for balancing of HCV adaptive T cell
responses, the association between these two factors
should be attractive and informative for the exploration
of mechanisms associated with HCV long-term persis-
tence. It was reported that Tregs proliferation and its
suppressive function were negatively regulated by PD-1/
PD-L1 pathway through a potentially novel mechanism
involving the prevention of IL-2 driven STAT-5 phos-
phorylation during chronic HCV infection [23,24]. How-
ever, detailed information with respect to PD-1
expression on different phenotypes (naïve/memory/
effector) of Tregs was not well understood.
Not only human CD8
+ T cells, but also CD4
+ T cells
could be divided into four different subsets (naïve, cen-
tral memory, effector memory and effector) according to
expression of maturation marker CD45RA or CD45RO
and another co-stimulating molecules (CD62L/CD27/
CCR7) [25-29]. CD4
+ Treg cells are a specialized subpo-
pulation of CD4
+ T cells that act to suppress activation
of the immune system and thereby its phenotype and
function could be studied through the similar classifica-
tion principles as used by total CD4
+ T cells. Addition-
a l l y ,s o m eg r o u p sh a v ea l r e a d ys t u d i e dt h ep h e n o t y p e
and function of Treg cells based on expression of
CD45RA and/or CD27 molecules [30-33]. In this study,
we aimed to investigate the distributional profiles
of Tregs subsets according to maturation markers
CD45RA and CD27 expression. Association between
PD-1 expression on these subsets and development of
HCV long-term persistence was also examined. Our
findings demonstrated that PD-1 expression on periph-
eral CD4
+CD127
loCD25
hi FoxP3
+ Tregs was elevated in
HCV chronically infected patients while the extent of
elevation was attenuated compared with other CD4
+
subsets. Additionally, the dominant proportion of per-
ipheral Tregs carried central memory phenotype in
chronic hepatitis C patients compared with nearly equal
contribution of naïve and central memory T cell in
healthy individuals.
Materials and methods
Study population
A total of 19 patients with chronic HCV infection were
enrolled in the study. All patients have more than
3-year history of commercial blood donations in early
1990 s. All these patients were positive for HCV antibo-
dies for the past 5 years and previous HCV test data
were collected from local CDC and hospital. HCV infec-
tion was confirmed by detectable plasma HCV RNA
(≥1.48 log10 IU/ml) measured by Abbott Real Time™
HCV Amplification Kit (Abbott Molecular Inc. Des
Plaines, IL, USA) and positive serum HCV antibodies
measured by ARCHITECT Anti-HCV system (Abbott
Molecular Inc. Des Plaines, IL, USA) according to the
manufacture’s instruction. HCV genotype was deter-
mined by amplifying and sequencing NS5b gene of
HCV genome. CD4
+/CD8
+ T cell counts and liver func-
tion associated enzymes were measured based on clini-
cal standard diagnostic criteria by the local Center for
Disease Control and Prevention. None of these HCV
infected patients received anti-HCV therapy. 17 non-
HCV infected individuals were recruited as healthy con-
trols. None of the participants showed evidence of
neither concomitant HBV or HIV infection, or other
non-viral causes of hepatic damage. The study was
approved by institutional review authorities of Peking
University Health Science Center and informed consent
was obtained from all participants prior to enrollment.
Flow Cytometry Analysis
Peripheral blood mononuclear cells (PBMC) were iso-
lated from heparinized blood by density gradient centri-
fugation using Ficoll-Hypaque (Sigma Chemical Co., St
Louis, MO, USA). Expression of surface markers on
CD4
+ T cells were analyzed by multi-parameter flow
cytometry on a FACSAria instruction (BD Biosciences,
San Jose, CA) compensated with single fluorochromes
and driven by FACSDiva software (BD Biosciences, San
Jose, CA). The following antibodies were used in this
study: anti-CD3-ECD, anti-CD4-APC-Cy7, anti-CD8-PE-
Cy7, anti-CD45RA-PE-Cy5, anti-CD27-PE, anti-CD25-
APC, anti-CD127-Pacific blue, anti-FoxP3-Alexa700, and
anti-PD-1-FITC (BD Pharmingen, San Diego, CA, USA).
Data analysis was performed by FlowJo software (Tree
Star, Inc., San Carlos, CA).
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Characteristics of the study population and the different
immune or biochemical parameters were recorded as
median and interquartile range. Comparisons between
groups were analyzed using non-parametric T tests
(Mann-Whitney test) or Wilcoxon match pairs test.
Correlations between quantitative parameters were ana-
lyzed using Spearman rank correlation coefficient test.
All statistical analysis was performed using GraphPad
Prism V5.0 (GraphPad Software Inc., San Diego, CA).
All P-values were two-tailed, and were considered signif-
icant when lower than 0.05.
Results
Characteristics of study subjects
Table 1 summarizes the main characteristics of 19
HCV-infected individuals. All data were described as
median (IQR1-IQR3). There was no significant differ-
ence in age and gender between chronic HCV infection
and healthy controls (data not shown).
The frequency of different CD4
+T cell subsets defined by
CD127 and CD25, CD45RA and CD27 respectively
Three subsets of CD4
+ T cells were defined by the expres-
sion of IL-2Ra (CD25) and IL-7Ra (CD127):CD127
+CD25
lo/-,C D 1 2 7
-CD25
-,a n dC D 1 2 7
loCD25
hi (Figure 1A).
Given that the most definitive markers available to identify
Tregs are the co-expression of CD25 and FoxP3, we
examined the expression of FoxP3 in the CD127
loCD25
hi
subsets which represented Tregs (Figure 1A). As shown in
Figure 1A, more than 95% of CD127
loCD25
hi subsets were
FoxP3 positive cells. The percentage of CD127
loCD25
hi-
FoxP3
+Tregs was increased in chronic hepatitis C (CHC)
patients compared with health controls (HCs) (p =0 . 0 3 3 8 )
(Figure 1B). On the contrary, decreased expression of
CD127
+CD25
lo/- subsets was observed in CHC patients
compared with HCs (p = 0.0032). No significant difference
was found in CD127
-CD25
- subsets distribution (p =
0.0759) (Figure 1B). CD4+T cells can be divided into four
different subsets depending on expression level of
CD45RA and CD27: naïve cells (CD27
+CD45RA
+), central
memory cells (CD27
+CD45RA
-), effector memory cells
(CD27
-CD45RA
-), and effector cells (CD27
-CD45RA
+)
(Figure 1A). The statistical results showed that the propor-
tion of naïve CD4
+T cells were declined in CHC patients
compared with HCs (p = 0.0004), while the other three
subsets (TCM, p = 0.0480; TEM, p = 0.0015; Effector T,
p = 0.0016)were all dramatically increased in CHC
patients(Figure 1C).
Expression of PD-1 on different CD4
+T cell subsets
defined by CD27 and CD45RA
T h eP D - 1e x p r e s s i o no nd i f f e r e n tC D 4
+Tc e l ls u b s e t s
defined by CD27 and CD45RA was determined by per-
centage of PD-1 positive cells and mean fluorescent
intensity (MFI) of PD-1. PD-1expression was signifi-
cantly increased in total CD4
+T cells and all four CD4
+T cell subsets (naïve/TCM/TEM/effector) in CHC
patients compared with HCs (Figure 2A, B, C). Of note,
expression of PD-1 was higher on TEM/effector subsets
than naive/TCM subsets in both CHC patients and HCs
(Figure 2B and 2C).
Expression of PD-1 on CD4
+CD127
loCD25
hiFoxP3
+ Tregs
We next examined and compared the expression profile of
PD-1 on different CD4
+Tc e l ls u b s e t sd e f i n e db yC D 1 2 7
and CD25. PD-1 expression was remarkably higher on all
three CD4+T cell subsets (CD127
+CD25
lo/-, CD127
-CD25
-,
and CD127
loCD25
hiFoxP3
+) in CHC patients compared
to HCs (p < 0.0001) (Figure 3A, B and 3C). In addition,
there was a significant decrease of PD-1 expression on
CD127
loCD25
hiFoxP3
+ Tregs compared with CD127
+CD25
lo/- (p < 0.0001 on percentage and MFI) or CD127
-
CD25
-(p = 0.0003 on percentage and p = 0.0045 on MFI) T
cell subsets in CHC patients (Figure 3B and 3C). The simi-
lar trend was found in CHC patients (Figure 3B and 3C).
The dominance of the central memory phenotype in CD4
+CD127
loCD25
hiFoxP3
+ Tregs in CHC patients
CD127
loCD25
hiFoxP3
+ Tregs were divided into Naïve-
Tregs, TCM-Tregs, TEM-Tregs, Effector-Tregs depending
Table 1 Demographics and clinical data of the HCV-
infected individuals enrolled in the current study
Characteristics HCV chronic infection
(n = 19)(Median (IQR1-IQR3))
Age (years) 51(40-58)
Gender(Male/Female) 12/7
HCV RNA(log10IU/ml) 6.14(5.76-6.56)
HCV Antibodies (S/CO ratio) 14.73(13.64-15.48)
HCV Antigens(log10fmol/L) 3.13(2.84-3.51)
Genotype(1b/2a) 6/13
CD4
+ T cell count/μL 716(477-950)
CD8
+ T cell count/μL 479(412-686)
ALT
a level(IU/mL) 36(26-50)
AST
b level(IU/mL) 36(32-48)
gGT
c level(IU/mL) 19(17-32)
ALP
d level(IU/mL) 65(56-81)
Albumin level(g/L) 43.70(41.60-47.20)
Total protein level(g/L) 76.40(73.14-79.40)
Ratio of albumin to globulin 1.37(1.18-1.54)
Total bilirubin level(μmol/L) 13.19(11.00-15.96)
Direct bilirubin level (μmol/L) 4.41(3.25-5.47)
Hemoglobin(g/L) 143(131-147)
aALT, Alanine aminotransferase;
bAST, Aspartate aminotransfearse;
cg - GT, g - glutamyltransferase;
dALP, Alkaline phosphatase.
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As shown in Figure 4B, the frequency of Naïve-Tregs was
dramatically reduced in CHC patients compared with HC
individuals (p < 0.0001), while expression of TEM/Effec-
tor-Tregs was dramatically enhanced in CHC patients
compared with HCs (p < 0.0001). No statistical difference
was observed regarding to the proportion of TCM-Tregs
in total CD4
+Tregs between CHC patients and HCs
(Figure 4B). It should be pointed out that the highest pro-
portion (nearly 50%) of Tregs carried central memory phe-
notype in CHC patients due to a decreased proportion of
naïve-Tregs (Figure 4B).
In addition, the distributional pattern of different CD4
+T cell subsets was evaluated and compared in total
CD4
+T cells and Tregs. The frequency of naïve cells dis-
played significantly declined trends from total CD4
+T
cells to Tregs (p < 0.0001) in both CHC and HCs. In
contrast, a significantly increased frequency of TCM
phenotype was found in Tregs compared with total CD4
+Tc e l l s( p < 0.0001) (Figure 4C). The proportion of
terminal differentiated effector cells was downregulated
in Tregs (p = 0.0003 in CHC and p = 0.0063 in HCs)
w h i l en od i f f e r e n c ei nT E Mf r e q u e n c yw a sf o u n d
between total CD4
+T cells and Tregs (Figure 4C).
Therefore, this results indicated that central memory
CD4
+T cells was the dominant subset in Tregs, instead
of naïve CD4+T cells which contributed to the majority
of subset in total CD4
+T cells.



Figure 1 Increased frequency of Treg cells (CD4
+CD127
loCD25
hiFoxP3
+) and effector memory/effector CD4
+ Tc e l ls u b s e t si n
peripheral blood of chronic HCV-infected patients. PBMCs were stained with T cell phenotyping markers (CD3, CD4, CD8, CD25, CD27,
CD45RA, CD127 and FoxP3) and analyzed for T cells subsets by flow cytometric analysis. (A): Representative examples of the gating strategy that
CD3
+CD4
+CD8
- T cells were divided into three subsets -CD127
-CD25
-, CD127
+CD25
lo/- and CD127
loCD25
hi, based on expression of CD25 and
CD127 or into four subsets- naïve, TCM, TEM and effector, based on expression of CD45RA and CD27. Additionally, more than 95% of
CD127
loCD25
hi T cells were further gated as FoxP3
+.( B): Comparison of CD4+ T cell subsets (CD127
-CD25
-, CD127
+CD25
lo/- and CD127
loCD25
hi
FoxP3
+) in chronic HCV infection (dark grey boxes) and healthy controls (open boxes). (C): Comparison of CD4
+ T cell subsets (naïve, central
memory, effector memory and effector) based on expressions of CD45RA and CD27 in chronic HCV infection (dark grey boxes) and healthy
controls (open boxes). Error bars illustrate s.d. *P < 0.05; **P < 0.01.
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+CD127
loCD25
hi
FoxP3
+ Tregs subsets defined by CD27 and CD45RA
PD-1 expression on different Tregs subsets was studied.
PD-1 expression was significantly higher on total Tregs
(p < 0.0001) and all four Tregs subsets (Naïve, p < 0.0001;
TCM, p < 0.0001; TEM, p < 0.0147; Effector, p < 0.0153)
in CHC patients compared with HCs. Besides, PD-1
expression was higher in TEM/effector-Tregs compared
with naïve/TCM-Tregs. TCM Tregs showed lower PD-1
expression than TEM subsets (CHC, p = 0.0125; HC, p <
0.0001) while higher than naïve subsets in both CHC
patients and HCs (CHC, p < 0.0001; HC, p < 0.0001)
(Figure 5A).
Since PD-1 expression was enhanced on all CD4
+T
cell subsets on both chronic HCV infected patients and
healthy controls, it is necessary and informative to com-
pare the ratio of TEM-Tregs to naive-Tregs and of
TEM-Tregs to TCM-Tregs regarding to PD-1 MFI
between CHC patients and HCs. The results shown in
Figure 5B indicated both TEM-Tregs/naïve-Tregs ratio
and TEM-Tregs/TCM-Tregs ratio were significantly
lower (p < 0.0001) in CHC patients than health controls.
Unfortunately, no correlation was found between these
ratios and peripheral HCV RNA level (data not shown).
Discussion
Both CD4
+CD127
loCD25
hi and CD4
+FoxP3
+were classic
phenotypes of regulatory CD4
+ T cells, which has been
described by accumulating literatures [34-36]. In the
present study, we employed CD4
+CD127
loCD25
hiFoxP3
+
cells as circulating natural Tregs to investigate distri-
butional characteristics of naïve, memory and effector
subsets of Tregs. PD-1 expression on Tregs and its sub-
sets was also studied in chronic HCV infected patients
and healthy controls. Previous studies demonstrated
human Tregs could be phenotypically and functionally
divided into resting Tregs (rTregs) and activated
Tregs (aTregs) according to the expression of surface
CD45RA. Both rTregs and aTregs were shown to sup-
press proliferation of CD25
- CD4
+ responder T cells in
vitro and CD45RA
- FoxP3
low/- subsets were non-Treg
cells since they had no suppressive function [30].


Figure 2 Percentage of PD-1 positive cells on total CD4
+ T cells and its subsets.( A): Representative dot plot analysis showing the
expression of PD-1 on total CD4
+ T cells and naïve, TCM, TEM, and effector subsets. PD-1 expressions on total CD4
+ T cells and all four subsets
were significantly higher in chronic HCV-infected patients (half black symbols) than in healthy controls (open symbols) presented by both
percentage (B) and MFI (C). *P < 0.05; **P < 0.01; ***P < 0.001.
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based on the expression of CD45RA and CD27 (a TNFR
family member) since total CD4
+ T cells could be subdi-
vided into four different subsets (naïve/central memory/
effector memory/effector) according to the expression of
CD45RA and CD27. Our results (Figure 4) indicated
that the proportion of Tregs in peripheral bulk CD4
+ T
cells was enhanced in CHC patients. The phenotypic
characteristics of Tregs were switched from nearly equal
contribution of naïve and central memory T cell of per-
ipheral Tregs in HCs to central memory T cell contri-
buting to be the dominant one in CHC patients,
suggesting that peripheral Tregs of CHC patients were
changed quantitatively and functionally.
PD-1/PD-L1 pathway was proved to play a critical role
in maintaining the balance between protective T cell
responses and immunopathology induced by hyper-
activated effector T cells [15,16,20,37-40]. It has been
reported that CD4
+ T-cell responses, including virus-
specific IFN-g production, were severely suppressed in
chronically HCV-infected subjects through PD-1/PD-L1
pathway [20]. Though PD-1 was demonstrated to be
expressed on Tregs and negatively regulated CD4
+CD25
+Foxp3
+ Tregs function by preventing STAT-5 phos-
phorylation in CHC patients [23], it was still far from
well understanding the molecular mechanisms of PD-1/
PD-L1 pathway involving in inhibition of CD4
+ T cell
function, including Foxp3
- effector T cells, Foxp3
- mem-
ory T cells and Tregs. Our data showed that PD-1
expression on total Tregs as well as its subsets was sig-
nificantly higher in HCV infected patients than healthy
controls (Figure 5A). This results were not consistent
with the hypothesis that chronic HCV infection was
associated with higher inhibitory effect of Tregs since


Figure 3 Percentage of PD-1 positive cells on CD127
-CD25
-,C D 1 2 7
+CD25
lo/- and CD127
loCD25
hi FoxP3
+ CD4+ T cell subsets.( A):
Representative dot plot analysis showing the expression of PD-1 on these three subsets. PD-1 expressions on these T cell subsets were
significantly higher in chronic HCV-infected patients (half black symbols) than in healthy controls (open symbols) presented by both of
percentage (B) and MFI (C). PD-1 expression on Treg cells (CD127
loCD25
hi FoxP3
+) was lower than on paired CD127
-CD25
- and CD127
+CD25
lo/-
subsets.
▵indicated that Wilcoxon match pairs test. *P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 4 The dominant proportion of the central memory phenotype was found in CD127
loCD25
hiFoxP3
+ Tregs in CHC patients.( A)
Representative dot plot analysis showing the phenotypic distribution of CD127
loCD25
hiFoxP3
+ Tregs depending on expression of CD27 and
CD45RA. (B) Frequency of Naïve -Tregs (□) was dramatically reduced in CHC patients compared with HCs while TEM (▥)/Effector (▦) -Tregs
showed a higher levels in CHC compared with in HCs. (C) The percentage of naïve and effector subset decreased while the percentage of TCM
subset increased in Tregs compared with in their total CD4
+ T cell counterparts. *P < 0.05; **P < 0.01; ***P < 0.001.
A B
Figure 5 (A) Increased MFI of TEM/effector Treg cells compared with naïve/TCM Treg cells in CHC patients and HC controls; (B)R a t i o so f
TEM-Tregs to naive-Tregs and TEM-Tregs to TCM-Tregs regarding to PD-1 MFI were significantly lower in CHC patients than in HCs.
▵indicated
that Wilcoxon match pairs test. *P < 0.05; **P < 0.01; ***P < 0.001.
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quent IL-2-driven STAT-5 phosphorylation. With
further investigation, we found (Figure 5B) that the
TEM-Tregs/naive-Tregs ratio and TEM-Tregs/TCM-
Tregs ratio of PD-1 MFI were significantly lower in
CHC patients than healthy controls, indicating that PD-
1 expression on TEM-Tregs or effector-Tregs were
inhibited in relative to its correspondent naïve- or
TCM-Tregs in CHC patients compared with healthy
controls. Theoretically, the relatively reduced PD-1
expression on TEM-Tregs and effector-Tregs could
enhance the inhibitory capacity of activated Tregs on
hyper-activated effector T cells, attributing to impaired
T cell immune response and subsequently inducing
long-term persistence of HCV infection.
Taken together, our findings provided insight into
the negative regulatory mechanism of Tregs and PD-1
on CD4
+T cell responses during chronic HCV infec-
t i o n .W ed e m o n s t r a t e dt h a tm o s tT r e g sd i s p l a y e da
central memory phenotype and PD-1 expression had a
trend of relatively lower upregulated expression on
effector Tregs and effector memory Tregs in relative to
their naïve- or TCM-Tregs counterparts in chronic
HCV infected patients compared with healthy indivi-
duals. The cross talk between Treg cells and PD-1
induced inhibition in chronic HCV infection and its
implication in dysfunction or impairment of CD4
+
T cell responses should be interesting and suggestive
for further exploration of persistent HCV infection
associated immune pathogenesis.
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